Stifel Financial Corp raised its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) by 3.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 99,133 shares of the company’s stock after purchasing an additional 3,733 shares during the period. Stifel Financial Corp owned 0.19% of TScan Therapeutics worth $494,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics during the second quarter worth approximately $70,000. The Manufacturers Life Insurance Company bought a new stake in TScan Therapeutics during the 2nd quarter valued at $90,000. SG Americas Securities LLC acquired a new position in TScan Therapeutics during the 3rd quarter worth $78,000. Cornercap Investment Counsel Inc. bought a new position in shares of TScan Therapeutics in the second quarter worth $134,000. Finally, MetLife Investment Management LLC grew its stake in shares of TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares in the last quarter. Institutional investors own 82.83% of the company’s stock.
TScan Therapeutics Trading Up 6.9 %
Shares of TCRX stock opened at $3.11 on Friday. The stock has a 50-day simple moving average of $4.37 and a 200 day simple moving average of $5.53. The stock has a market capitalization of $165.98 million, a P/E ratio of -2.93 and a beta of 0.79. TScan Therapeutics, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.
Wall Street Analyst Weigh In
TCRX has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Wednesday, December 11th.
Get Our Latest Analysis on TScan Therapeutics
About TScan Therapeutics
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Recommended Stories
- Five stocks we like better than TScan Therapeutics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Top 3 Investment Themes to Watch for in 2025
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- The How And Why of Investing in Oil Stocks
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.